Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

SARS-CoV-2-Specific CD8+ T Cells in Blood but Not in the Lungs of Vaccinated K18-hACE2 Mice after Infection

Version 1 : Received: 29 July 2023 / Approved: 31 July 2023 / Online: 1 August 2023 (02:33:49 CEST)

A peer-reviewed article of this Preprint also exists.

Ferrantelli, F.; Manfredi, F.; Chiozzini, C.; Leone, P.; Pugliese, K.; Spada, M.; Di Virgilio, A.; Giovannelli, A.; Valeri, M.; Cara, A.; Michelini, Z.; Andreotti, M.; Federico, M. SARS-CoV-2-Specific CD8+ T-Cells in Blood but Not in the Lungs of Vaccinated K18-hACE2 Mice after Infection. Vaccines 2023, 11, 1433. Ferrantelli, F.; Manfredi, F.; Chiozzini, C.; Leone, P.; Pugliese, K.; Spada, M.; Di Virgilio, A.; Giovannelli, A.; Valeri, M.; Cara, A.; Michelini, Z.; Andreotti, M.; Federico, M. SARS-CoV-2-Specific CD8+ T-Cells in Blood but Not in the Lungs of Vaccinated K18-hACE2 Mice after Infection. Vaccines 2023, 11, 1433.

Abstract

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 enters the host by infecting nasal ciliated cells. Then, the virus can spread towards the oropharyngeal cavity and the pulmonary tissues. The antiviral adaptive immunity is promptly induced in response to virus detection, with virus-specific T lymphocytes appearing before antiviral antibodies. Both breadth and potency of the antiviral CD8+ T cell immunity have a key role in containing viral spread and disease severity. Current anti-SARS-CoV-2 vaccines do not impede the virus replication in the upper respiratory tract, and there is consensus on the fact that the best potency of the antiviral immune response in both blood and upper respiratory tract can be reached upon infection in vaccinees (i.e., breakthrough infection). However, whether the antiviral CD8+ T cells developing in response to the breakthrough infection in the upper respiratory tract diffuse to the lungs also is still largely unknown. To fill the gap, we checked the CD8+ T cell immunity elicited after infection of K18-hACE2 transgenic mice both 3 weeks and 3 months after anti-Spike vaccination. The virus-specific CD8+ T cell immunity was monitored in both blood and the lungs before and after infection. By investigating the de novo generation of CD8+ T cells specific for SARS-CoV-2 viral proteins, we found that both membrane (M) and/or nucleocapsid (N)-specific CD8+ T cells were induced at comparable levels in blood of both unvaccinated and vaccinated mice. Conversely, N-specific CD8+ T cells were readily found in the lungs of control mice, but were either rare or absent in those of vaccinated mice. These results support the idea that the hybrid cell immunity developing after asymptomatic/mild breakthrough infection strengthens the antiviral cell immunity at lungs only marginally, implying that the direct exposition of the viral antigens is required for the induction of an efficient antiviral cell immunity in the lungs.

Keywords

SARS-CoV-2; CD8+ T cell immunity; vaccines; K18 transgenic mice

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.